Stock Track | Tempus AI Stock Soars on Anticipated Conference Presentations

Stock Track

Nov 08, 2024

Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.

Among the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124278140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124278140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124278140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124278140","market":"us","top_or_hot":-1,"title":"Stock Track | Tempus AI Stock Soars on Anticipated Conference Presentations","media":"Stock Track","content":"<p>Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.</p>\n\n<p>The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.</p>\n\n<p>Among the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tempus AI Stock Soars on Anticipated Conference Presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Stock Soars on Anticipated Conference Presentations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.</p>\n\n<p>The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.</p>\n\n<p>Among the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1124278140","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124278140","pubTimestamp":1731078088,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Tempus AI , a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer  Annual Meeting.The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.Among the key presentations,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"股票跟踪Tempus AI股票因预期的会议演讲而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.\nThe abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.\nAmong the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}